Kalytera Therapeutics to Announce Phase 2a Clinical Study Results Investigating CBD for the Treatment of Acute Graft versus H...
February 16 2017 - 4:30PM
Kalytera Therapeutics, Inc. (TSXV:KALY) (“Kalytera”) will announce
the results of a Phase 2a study investigating the safety and
efficacy of cannabidiol (“CBD”) for the treatment of acute (Grades
3-4) Graft versus Host Disease (“GvHD”) on Wednesday, February 22,
2017. A conference call and webcast will be held on Thursday,
February 23, 2017 at 12:00 PM ET to discuss the study results.
The Phase 2a study was conducted by Talent Biotechs, Ltd.
(“Talent”), an Israeli-based company evaluating the use of CBD to
prevent and treat GvHD, that has been newly acquired by
Kalytera.
GvHD is a multisystem disorder that is a common,
life-threatening complication of hematopoietic stem cell transplant
(“HCT”) procedures. HCT is a lifesaving procedure for many diseases
of the blood and bone marrow including leukemia, Hodgkin and
Non-Hodgkin lymphoma, and multiple myeloma. GvHD occurs when the
transplanted donor cells attack the patient’s organs, including the
skin, gastrointestinal tract, liver, lungs, and eyes. GvHD is
associated with acute and chronic illness, infections, disability,
reduced quality of life, and death.
The Phase 2a treatment study enrolled ten patients with acute
GvHD, including five patients with Grade 3 GvHD and five patients
with Grade 4 GvHD. All ten patients were steroid refractory,
meaning that they had not responded to previously administered
standard of care steroid treatment. Patients were administered
daily doses of CBD for up to three months, alongside standard of
care therapy.
Conference Call and Webcast Information
- Date: Thursday, February 23, 2017
- Time: 12:00 PM ET
- Conference
Call: http://dpregister.com/10101838 (Register to
receive dial-in instructions)
-
Webcast: http://services.choruscall.com/links/kaly170223.html
(Allow at least ten minutes to access the site before the
webcast begins)
The conference call and webcast will be available for replay on
the Kalytera website.
About Kalytera TherapeuticsKalytera (TSXV:
KALY) is pioneering the development of a next generation of
cannabinoid therapeutics. Through its proven leadership, drug
development expertise, and intellectual property portfolio,
Kalytera seeks to establish a leading position in the development
of novel cannabinoid medicines for a range of important unmet
medical needs, with an initial focus on Graft versus Host Disease
(“GvHD”).
Kalytera is focused first on developing a new class of
proprietary cannabidiol (“CBD”) therapeutics. CBD is a remarkable
compound that has shown activity against a number of
pharmacological targets. However, there are limitations associated
with natural CBD, including its poor oral bioavailability and short
half-life. Kalytera is developing innovative CBD formulations and
prodrugs in an effort to overcome these limitations, and to target
specific disease sites within the body. Kalytera intends to file
composition of matter and method of use patents covering its novel
inventions, with the goal of limiting future competition.
- Website Home: https://kalytera.co/
- News and Insights: https://kalytera.co/news/
- Investors: https://kalytera.co/investors/
Cautionary NoteNeither the TSXV nor its
Regulation Services Provider (as that term is defined in the
policies of the TSXV) has in any way passed upon the merits of the
proposed Transaction and associated transactions and neither of the
foregoing entities has in any way approved or disapproved of the
contents of this press release.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
Forward-Looking Statement DisclosureThis news
release contains “forward-looking information” within the meaning
of applicable securities laws, including information relating to
the Phase 2a clinical trial. Although Kalytera believes in light of
the experience of its officers and directors, current conditions
and expected future developments and other factors that have been
considered appropriate, that the expectations reflected in this
forward-looking information are reasonable, undue reliance should
not be placed on them because Kalytera can give no assurance that
they will prove to be correct. Readers are cautioned to not place
undue reliance on forward-looking information. Actual results and
developments may differ materially from those contemplated by these
statements depending on, among other things, the risks of failure
of the results of the Phase 2a clinical trial to be consistent with
the preliminary results of such trial, that the Phase 2a clinical
trial results are not determinative of or consistent with the
results of the results of future Phase 2 or other clinical studies,
that the small number of patients in the Phase 2a clinical trial
may contribute to the risk that future studies may be inconsistent
with the results of the Phase 2a clinical trial, and that clinical
trials are subject to a number of other health, safety, efficacy
and regulatory risks. The statements in this press release are made
as of the date of this release. Kalytera undertakes no obligation
to comment on analyses, expectations or statements made by
third-parties in respect of Kalytera, Talent, their securities, or
their respective financial or operating results (as applicable).
Kalytera disclaims any intent or obligation to update publicly any
forward-looking information, whether as a result of new
information, future events or results or otherwise, other than as
required by applicable securities laws.
Company Contact
Robert Farrell
President, COO and CFO
Phone: (888) 861-2008
Email: ir@kalytera.co
Kalytera Therapeutics (TSXV:KALY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kalytera Therapeutics (TSXV:KALY)
Historical Stock Chart
From Apr 2023 to Apr 2024